Could a common diabetes pill boost Teplizumab's effects in early type 1 diabetes?
NCT ID NCT06338553
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether adding a GLP-1 drug (semaglutide, sold as Rybelsus®) to the standard teplizumab treatment can help control blood sugar and improve blood vessel function in people with early stage type 1 diabetes. Researchers will give 24 participants a liquid meal test with and without the drug, measuring blood sugar, insulin, and artery health. The goal is to see if this combination can better manage the disease and reduce heart risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (Rybelsus®)
What this could lead to
If it works, this could point toward a way to better manage blood sugar and protect blood vessels in people with early type 1 diabetes who are already receiving teplizumab.
What could go wrong
This is a very small, early-phase pilot study with only 24 participants. It is designed to test short-term effects, not long-term outcomes, and may not lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••